Identifying factors that lead to antibiotic resistance in bacteria
Genome-driven identification of patient and bacterial drivers of resistance to novel beta-lactam/beta-lactamase inhibitor combination therapies
This study is looking at how different patient traits and bacteria work together to make infections harder to treat with new antibiotics, and it's for anyone interested in understanding how we can better fight resistant infections.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10994492 on NIH RePORTER |
What this research studies
This research investigates how certain patient characteristics and bacterial traits contribute to the development of resistance against new antibiotic therapies. By analyzing data from patients and bacteria, the study aims to understand the interactions that lead to antibiotic resistance, particularly focusing on two new combination therapies. The research will involve collecting and analyzing clinical data and bacterial samples to identify patterns and drivers of resistance. This information could help in developing strategies to prevent the spread of resistant infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who are infected with carbapenem-resistant Klebsiella pneumoniae or are at risk of such infections.
Not a fit: Patients with infections caused by bacteria that are not carbapenem-resistant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with antibiotic-resistant infections.
How similar studies have performed: Previous research has shown success in identifying resistance mechanisms in bacterial infections, suggesting that this approach could yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Gontjes, Kyle James — University of Michigan at Ann Arbor
- Study coordinator: Gontjes, Kyle James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.